Freshworks Inc. ( FRSH ) is a company that has found a position in my portfolio. Since I last covered it, the stock saw a pretty good decrease, dropping from near $12.5 a share down to a 52-week lowAnalyst’s Disclosure:I/we have a beneficial long position in the shares of FRSH either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with ...

Well, thanks for u picking this up, Dan, and uh reaching out to us because we did issue a statement uh on our website today, an official statement to clarify that there was a misrepresentation by some media about our monthly market report which was issued I believe on the 12th of November last week. uh specifically regarding the messages and a narrative that was being created out of reading some of our numbers. For example, things related to the market being in a surplus next year 2026 according and the rep ...

Core Viewpoint - Honda Motor is set to gradually resume normal operations at its North American vehicle assembly plants starting Monday, indicating a recovery from production disruptions caused by a shortage of Nexperia chips [1] Group 1 - Honda Motor's North American vehicle assembly plants will begin normal operations again, signaling a positive shift in production capabilities [1] - The production disruptions were primarily due to a shortage of Nexperia chips, which affected the automotive supply chain [1]

This judgement came in a case filed by Mr. Mallick, a retired employee of the Rail Coach Factory, Mancheswar, and currently a pensioner maintaining a bank account with the State Bank of India (SBI). His monthly pension is around Rs 35,000, and it is his main source of income. Mallick acted as a guarantor for his wife’s transport vehicle loans and signed Guarantee Agreements to that effect. She had taken out several loans from the bank, including two transport vehicle loans for Rs 5.9 lakh and Rs 8 lakh, as ...

SynopsisA key Apple designer, Abidur Chowdhury, has departed the company. Chowdhury was instrumental in developing the iPhone Air and even featured in its launch video. His exit adds to recent changes within Apple's design team. Many long-term members have left since Jony Ive's departure. The design group now comprises new recruits and junior staff. ...

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors about the effectiveness and prospects of its lead drug candidate, nimacimab [1][2]. Company Overview - Skye Bioscience, Inc. is a clinical stage biopharmaceutical company focused on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases [1]. Allegations - The lawsuit claims that during the class period, Skye failed to disclose that nimacimab was less effective than previously stated, leading to overstated clinical, regulatory, and commercial prospects [2]. - On October 6, 2025, Skye announced that nimacimab did not achieve its primary endpoint of weight loss compared to placebo in a Phase 2a study, resulting in a significant stock price drop of $2.85 per share, or 60%, closing at $1.90 per share [3]. Legal Proceedings - Shareholders may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiff [4]. - The representation in the lawsuit is on a contingency fee basis, meaning shareholders will not incur fees or expenses [5].

The index fell as much as 3.3% to 48,661,52, hitting its lowest level since October 23, as the selloff accelerated in the afternoon session. It was last down 3% at 48,808.33, as of 0502 GMT, while the broader Topix slipped 2.49% to 3,264.11. "Once the Nikkei fell below the key 50,000 level, sentiment worsened and the sell-off accelerated," said Seiichi Suzuki, chief equity market analyst at Tokai Tokyo Intelligence Laboratory. "Some investors wanted to buy shares on a dip, but even they waited for shares t ...

Market Analysis by covering: Alphabet Inc Class A, Apple Inc, Berkshire Hathaway B. Read 's Market Analysis on Investing.com ...

Core Insights - The article discusses the potential mispricing of sonelokimab's approval probability and commercial potential in the biotech sector, suggesting that the market has not accurately assessed its value [4]. Group 1: Author's Background - The author has over a decade of experience in financial research, investment advisory, and banking analytics, with a focus on evaluating institutional strengths and weaknesses [2]. - The author's academic background includes a Bachelor's in Business Economics and an MBA, which informs their analytical approach to market valuation [2]. - Since retiring from full-time industry work in 2018, the author has concentrated on independent investment research, particularly in overlooked and under-owned assets [2]. Group 2: Research Focus - The research emphasizes the importance of macroeconomic trends, data science, and qualitative analysis to uncover actionable insights and market inefficiencies [2]. - The author aims to provide value to investors by bridging analytical rigor with strategic foresight, focusing on market psychology and valuation [2]. Group 3: Investment Position - The author holds a beneficial long position in MLTX shares, indicating a personal financial interest in the stock [3].

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...